Theranostics combines molecular imaging with targeted treatment, allowing clinicians to identify suitable patients and then treat the same biological target.
See What Is Happening Inside Companies And What It Means For Customers And Your Business. Download Sample: https://www.towardshealthcare.com/download-sample/6009
The approach is gaining momentum in prostate cancer and neuroendocrine tumors, but wider adoption is still constrained by infrastructure, isotope supply, specialist workforce, reimbursement and treatment capacity.
The biggest challenge is that theranostics requires an entire healthcare ecosystem, not simply an approved drug.
The 10 Biggest Adoption Barriers
| Barrier | What it means for healthcare systems | Adoption impact |
|---|---|---|
| Infrastructure | Requires nuclear medicine, imaging and radiation-shielded facilities | High |
| Workforce | Requires nuclear medicine physicians, physicists and radiopharmacists | High |
| Radioisotope supply | Lu-177 and Ac-225 require specialized production | High |
| Logistics | Radioactive products have limited usable time | High |
| Treatment cost | Drug + imaging + facilities + staffing increase total cost | High |
| Reimbursement | Multiple treatment and diagnostic components must be covered | High |
| Patient selection | Requires molecular imaging and target confirmation | Medium–High |
| Geographic access | Services are concentrated in specialist centers | High |
| Regulation | Pharmaceuticals and radioactive materials have overlapping requirements | Medium–High |
| Clinical evidence | Long-term evidence is still developing across indications | Medium |
1. Limited Nuclear Medicine Infrastructure
One of the biggest barriers is the availability of specialized treatment infrastructure.
Radioligand therapy may require:
- Radiation-shielded treatment rooms
- PET/CT or SPECT imaging
- Nuclear medicine departments
- Radiopharmacy facilities
- Radiation monitoring
- Specialized waste management
- Qualified technologists and physicians
The International Atomic Energy Agency estimates that more than 10 million nuclear medicine procedures are performed globally each year, but access remains highly uneven between regions.
For hospitals, this means a therapy can receive regulatory approval without every healthcare system having the infrastructure needed to deliver it.
2. Shortage of Specialized Workforce
Theranostics requires a multidisciplinary workforce.
Key professionals include:
Nuclear medicine physicians | Medical physicists | Radiopharmacists | Nuclear medicine technologists | Oncologists | Dosimetrists | Radiation-safety specialists
The U.S. Bureau of Labor Statistics projects nuclear medicine technologist employment to decline 1% from 2024–2034.
This creates a potential capacity problem as demand for radiopharmaceutical therapies grows.
Why workforce matters
A hospital may have the treatment room and isotope supply but still be unable to expand treatment volumes if it cannot recruit and retain trained specialists.
3. Radioisotope Supply Is a Critical Constraint
Theranostics depends heavily on medical radioisotopes including:
- Lutetium-177
- Actinium-225
- Gallium-68
- Iodine-131
The logistics are fundamentally different from conventional pharmaceuticals.
| Isotope | Approximate half-life | Strategic relevance |
| Lu-177 | 6.65 days | Established radioligand therapy |
| Ac-225 | 9.9 days | High-interest alpha therapy |
| Ga-68 | 67.7 minutes | Molecular imaging |
| I-131 | 8 days | Established nuclear medicine applications |
Because radioactive materials decay continuously, manufacturers and hospitals need reliable coordination between production, radiolabeling, quality control, transportation and administration.
Actinium-225 presents an additional challenge because production capacity remains limited relative to potential future demand.
4. High Total Treatment Costs
Theranostics should not be evaluated only on the price of the radiopharmaceutical.
Healthcare systems may also need:
- PET/CT or SPECT scanners
- Radiation-shielded rooms
- Radiopharmacy infrastructure
- Dosimetry
- Additional staffing
- Radiation monitoring
- Patient management
- Specialized transportation
This makes the total cost of ownership particularly important for hospitals.
5. Reimbursement Remains Complex
Theranostics combines several healthcare services:
Diagnostic imaging + biomarker assessment + radiopharmaceutical + administration + monitoring
Each component may involve different reimbursement rules.
For U.S. providers, payment can vary according to:
- Indication
- Payer
- Treatment setting
- Drug
- Administration requirements
- Diagnostic services
Uncertain reimbursement can therefore delay infrastructure investment.
6. Patient Selection Requires Molecular Imaging
Theranostics works by identifying a biological target and then treating that target.
Examples include:
PSMA imaging → PSMA-targeted therapy
Somatostatin receptor imaging → targeted radioligand therapy
Patients therefore need accurate molecular imaging before treatment.
If PET imaging capacity is limited, the diagnostic step itself can become a bottleneck.
7. Geographic Access Is Uneven
Theranostics is currently concentrated in specialized cancer and academic centers.
Access can be more difficult for:
- Rural patients
- Community hospitals
- Lower-income healthcare systems
- Countries with limited nuclear medicine infrastructure
Patients may therefore need to travel significant distances for diagnosis and treatment.
8. Regulatory Complexity
Theranostics operates at the intersection of several regulatory areas.
Healthcare organizations may need to manage requirements covering:
- Pharmaceutical products
- Radiopharmaceutical manufacturing
- Radioactive materials
- Radiation safety
- Medical imaging
- GMP
- Transportation
This can make commercialization and implementation more complicated than conventional medicines.
9. Clinical Evidence Is Strongest in Selected Cancers
The clinical case for theranostics has strengthened significantly in prostate cancer and neuroendocrine tumors.
Key clinical evidence
| Study | Therapy | Patients | Key result |
| VISION | Lu-177-PSMA-617 | 831 | 38% reduction in risk of death |
| NETTER-1 | Lu-177 DOTATATE | 229 | Significant progression-free survival benefit |
The Phase III VISION trial demonstrated that Lu-177-PSMA-617 plus standard care reduced the risk of death by 38% versus standard care alone in metastatic castration-resistant prostate cancer.
However, evidence remains less mature for many emerging targets and indications.
Healthcare systems therefore need to distinguish between established clinical evidence and emerging applications.
10. Treatment Capacity Can Become the Next Bottleneck
As more patients become eligible, hospitals may face capacity constraints involving:
- Treatment rooms
- Imaging slots
- Radiopharmacy throughput
- Isotope availability
- Specialist staffing
- Patient scheduling
- Radiation-safety procedures
This creates an important strategic issue:
Growing demand does not automatically translate into growing treatment volumes.
Capacity has to grow at the same time.
Who Is Affected by These Barriers?
| Stakeholder | Main challenge |
| Hospitals | Infrastructure, staffing and capital investment |
| Oncologists | Treatment pathways and patient selection |
| Nuclear medicine departments | Capacity and isotope availability |
| Pharma companies | Manufacturing and isotope supply |
| Radiopharmaceutical manufacturers | Production and short half-lives |
| Payers | Demonstrating clinical and economic value |
| Patients | Availability, travel and waiting times |
| Investors | Infrastructure and commercial scalability |
What Is Changing in 2025–2026?
Investment is increasingly moving toward:
- Radioligand therapy
- Actinium-225 production
- Lutetium-177 manufacturing
- Molecular imaging
- Automated radiopharmacy
- Radiopharmaceutical CDMOs
- Dosimetry technology
- Personalized treatment planning
Large pharmaceutical companies are also expanding radiopharmaceutical strategies through M&A, licensing, partnerships and internal R&D.
This means competitive advantage may increasingly depend on supply-chain security and treatment infrastructure, not just pipeline quality.
What Should Healthcare Systems Track?
Healthcare organizations evaluating theranostics should monitor:
- Eligible patient populations
- PET/CT availability
- Treatment-room capacity
- Isotope supply
- Radiopharmacy capacity
- Specialist workforce
- Reimbursement
- Treatment economics
- Clinical evidence
- Regional referral networks
A Practical Readiness Framework
| Readiness area | Key question |
| Patients | How many eligible patients can we treat annually? |
| Diagnostics | Can we perform molecular imaging at sufficient volume? |
| Infrastructure | Do we have appropriate treatment rooms? |
| Isotopes | Can we secure reliable long-term supply? |
| Workforce | Do we have trained specialists? |
| Economics | Is reimbursement sufficient to support treatment? |
| Logistics | Can short-lived products reach patients on schedule? |
| Evidence | Which indications have the strongest clinical support? |
| Referrals | Can eligible patients be identified efficiently? |
| Scalability | Can today’s infrastructure support future therapies? |
The Strategic Takeaway
Theranostics is moving from a specialized technology toward a potentially important component of precision oncology.
The clinical evidence is strongest in selected cancers, while investment is expanding across radioligands, isotope production, imaging and manufacturing.
But widespread adoption will depend on solving the delivery challenge.
The key question for healthcare systems is:
Can we build the infrastructure, workforce, isotope supply, reimbursement model and referral network required to deliver theranostics at scale?
Towards Healthcare Research & Consulting helps pharmaceutical companies, healthcare providers and investors track theranostic pipelines, clinical trials, radiopharmaceutical manufacturing, isotope supply, facilities, investments, partnerships, reimbursement and regional adoption.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium